-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651.O2.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational III

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, apoptosis, Biological therapies, Antibody Therapy, Non-Biological therapies, Bispecific Antibody Therapy, Translational Research, Plasma Cell Disorders, bioinformatics, Combination therapy, Hemoglobinopathies, drug development, Diseases, immune mechanism, Therapies, immunology, Immunotherapy, Lymphoid Malignancies, computational biology, Biological Processes, Pharmacology, Technology and Procedures, molecular biology, omics technologies
Saturday, December 10, 2022: 4:00 PM-5:30 PM
New Orleans Theater C (Ernest N. Morial Convention Center)
Jo Caers, PhD, CHU de Liège and Marta Chesi, PhD, Department of Medicine, Mayo Clinic Arizona
Chesi: Pfizer, Novartis.: Consultancy, Research Funding; Abcuro, Palleon Pharmaceuticals,, Pi Therapeutics.: Patents & Royalties: Genetically engineered mouse model of myeloma..
4:00 PM

Luciano Nicosia, PhD1*, Nigel Brooks, PhD2*, Fabio Amaral, PhD1*, Oliver Sinclair1*, Neil A Pegg2*, William West, PhD, MSc, MBA2*, Tomasz Knurowski, PhD, MD2*, Kris Frese, PhD2*, Karen Clegg, PhD2*, James Cavet, PhD FRCP FRCPath3*, Emma Searle4,5* and Tim C.P Somervaille, PhD FRCP FRCPath1

1Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
2CellCentric Ltd, Cambridge, United Kingdom
3Haematology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
4The University of Manchester, Manchester, United Kingdom
5The Christie Hospital, University of Manchester, Manchester, United Kingdom

4:15 PM

Tengteng Yu, MD1*, Mu Hao, PhD2*, Hailin Chen, MD1*, Kenneth Wen1*, Tingjian Wang, MD3*, Thomas C.M Smits4*, Mehmet K. Samur, PhD4*, Eugenio Morelli, MD5, Lijie Xing, MD6*, Liang Lin, PhD1*, Jun Qi, PhD3*, Gang An, MD2*, Nikhil C Munshi, MD, PhD1, Yu-Tzu Tai, PhD1, Lugui Qiu2 and Kenneth C. Anderson, MD1

1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
5Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
6Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

4:30 PM

Aisha Jibril, BSc1*, Charlotte Hellmich, MBBChair1,2*, Jamie A Moore, BSc, MSc1*, Jayna J Mistry, PhD1*, Rebecca S Maynard, MSc1*, Katherine Hampton, MSc, BSc1*, Kristian M Bowles, MBBS, PhD1,2 and Stuart A Rushworth, PhD1

1Norwich Medical School, University of East Anglia, Norwich, United Kingdom
2Department of Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

4:45 PM

Enrico Milan, PhD1,2*, Massimo Resnati3*, Elena Riva3*, Mario Nuvolone, MD, PhD4* and Simone Cenci, MD1,2

1Vita-Salute San Raffaele University, Milano, Italy
2Laboratory of Age Related Diseases, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy
3Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy
4Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy

5:00 PM

Maria Pihlgren, PhD1*, Olivia Hall, PhD1*, Laura Carretero, PhD1*, Carole Estoppey, PhD1*, Adam Drake, PhD1*, Daniela Pais, PhD1*, Jeremy Loyau, PhD1*, Jeremy Berret1*, Isabelle Gruber, PhD1*, Perrine Suere1*, Vincent Schnorhk1*, Emilie Nallet1*, Blandine Pouleau1*, Myriam Chimen, PhD1*, Julie Macoin1*, Elodie Stainnack1*, Thierry Monney, PhD1*, Aurore Delachat, PhD1*, Cyrille Dreyfus, PhD1*, Thomas Matthes, MD2, Cyril Konto, MD3, Michael Dyson, PhD1*, Stanislas Blein, PhD1*, Lamine Mbow, PhD1, Rebecca Wood, PhD1*, Ankita Srivastava, PhD1*, Eugene Zhukovsky, PhD1 and Mario Perro, PhD1*

1Ichnos Sciences Biotherapeutics SA, Lausanne, Switzerland
2Service d’Hématologie, Université de Genève, Onex, Switzerland
3Ichnos Sciences, New York

5:15 PM

Romanos Sklavenitis-Pistofidis, MD1,2,3, Ting Wu, MS2*, Mahshid Rahmat, PhD1,2,3*, Yoshinobu Konishi, MD, PhD1,2,4*, Elizabeth D. Lightbody, PhD1,2,3, Michael Timonian, MD1,2,3*, Junko Tsuji, PhD2*, Danielle T. Firer, BS2*, Nicholas J. Haradhvala, PhD2*, Cinnie Yentia Soekojo, MD1,3, Xiyue Wang, MS3*, Daniel Heilpern-Mallory, BS3*, François Aguet, PhD2*, Gad Getz, PhD1,2,5* and Irene Ghobrial, MD1,2,3

1Department of Medicine, Harvard Medical School, Boston, MA
2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
5Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA

*signifies non-member of ASH